Trials / Completed
CompletedNCT02523391
Bioequivalence Study of Capsule and Tablet Formulations of TA-8995
A Phase I, Randomised, Open-label Cross-over Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Xention Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the pharmacokinetics of capsule and tablet formulations of TA-8995 in healthy male subjects aged 18 to 55 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TA-8995 | Capsule |
| DRUG | TA-8995 | Tablet |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2015-08-14
- Last updated
- 2016-01-29
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02523391. Inclusion in this directory is not an endorsement.